How to make the best use of limited resources in breast cancer treatment - Experiences in Bosnia and Herzegovina

Journal of B.U.ON.

Volumn 11, Issue 1, 2006, Pages 21-29

  Obralić, Nermina ^a   Beslija S ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Breast cancer; Treatment; Treatment costs

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; GOSERELIN; LETROZOLE; METHOTREXATE; ONDANSETRON; PACLITAXEL; PAMIDRONIC ACID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEX HORMONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BONE METASTASIS; BOSNIA AND HERZEGOVINA; BREAST CANCER; BUDGET; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DRUG COST; DRUG MEGADOSE; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; EXPERIENCE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HORMONAL THERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MASTECTOMY; MEDICAL LITERATURE; PREDICTION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BOSNIA-HERZEGOVINA; BREAST NEOPLASMS; COST OF ILLNESS; FEMALE; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICALLY UNDERSERVED AREA;

EID: 33646708702     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Parkin MD, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 330-364.
2. Brown P. UK death rates from breast cancer fall by a third. Br Med J 2000; 321: 849.
3. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer death down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1882.
4. Tabar R, Vitak B, Chen HHT, Yen MF, Duffy SW, Smith RA. Beyond randomised control trials; Organised mammography screening substantially reduces breast carcinoma mortality. Cancer 2001; 91: 1724-1731.
5. Beauchamp TL, Childress JF (eds). Principles ofbiomedical ethics. Oxford University Press, Oxford, 1994.
6. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Cancer Base No. 5, Lyon, IARC Press, 2001.
7. Register of Malignant Tumours of Clinical Centre, University of Sarajevo. Sarajevo 2002.
8. Obralić N, Gavrankapetanović F, Dizdarević Z et al. Regional comparison of cancer incidence. Radiol Oncol 2004; 38: 145-151.
9. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trails. N Engl J Med 1995; 333: 1444-1455.
10. Liljewrgen G, Holmberg L, Bergh J et al. 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: A randomised trial. J Clin Oncol 1999; 17: 2326-2333.
11. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects of long - term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355: 1757-1770.
12. Veronesi U, Luini A, Galimberti V et al. Conservation approaches for the management of the stages I/II carcinoma of the breast: Milan Cancer Institute Trials. Wld J Surg 1994; 18: 70-75.
13. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
14. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 17: 931-942.
15. French Adjuvant Study Group. Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol 2001; 16: 602-611.
16. Citron ML, Berry DA, Cirrincione C. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
17. Henderson IC, Berry D, Demetri G et al. Improved disease free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 1998; 17: 101a (abstr).
18. Thomas E, Buzdar A, Theriault R at al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of a prospective randomised clinical trial. Proc Am Soc Clin Oncol 2000; 19: 74a (abstr).
19. Henderson C, Berry DA, Demetri GD et al. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. J Clin Oncol 2003; 21: 976-983.
20. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Proc San Antonio Breast Cancer Meet 2003 (abstr #45).
21. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28896 women. N Engl J Med 1988; 319: 1681-1692.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overiew of the randomised trials. Lancet 1998; 351: 1451-1467.
23. Jakesz R, Hausmaninger H, Kubistra E et al. Randomised adjuvant trial of tamoxifen and goserelin versus CMF. Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone responsive breast cancer- Austrian Breast & Colorectal Cancer Study Group Trial 5 . J Clin Oncol 2002; 20: 4621-4627.
24. Klijn JGM, Beex L, Mauriac L et al. Combined treatment with buserelin and tamoxifen versus tamoxifen alone in premenopausal women with early breast cancer: a randomized study. J Natl Cancer Inst 2000; 92: 903-911.
25. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
26. Coombes RC, Hall E, Gibson L et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 82 (Suppl): S6 (abstr #1).
27. ATAC Trialists Group. Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359: 2131-2139.
28. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
29. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
30. Howell A, Cuzick J, Baum M, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
31. Honig SF. Treatment of metastatic disease. In: Harris JR, Lippman ME, Morrow M et al (eds): Diseases of the Breast. Philadelphia: Lippincott-Raven Publ, 1996, pp 669-734.
32. Falkson G, Holcroft C, Gelman RS et al. Ten-year follow-up study of premenopausal women with metastatic breast cancer; an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1453-1458.
33. Yeatman TJ. The natural history of locally advanced primary breast carcinoma and metastatic disease. Surg Oncol Clin N Am 1995; 4: 569-589.
34. Cardoso F, Di LA, Lohrisch C et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002; 13: 197-207.
35. Norton L. Salvage chemotherapy of breast cancer. Semin Oncol 1994; 21: 19-24.
36. Bull JM, Tormey DC, Li SH et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978; 41: 1649-1657.
37. Cummings FJ, Gelman R, Horton J et al. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol 1985; 3: 932-940.
38. Falkson G, Tormey DC, Carey P et al. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer 1991; 27: 973-977.
39. Bontenbal M, Braun JJ, Creemers GJ et al. Phase III study comparing AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur J Cancer 2003; 1: 5201-5202.
40. Biganzoli L, Cufer T, Bruning P et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002; 20: 3114-3121.
41. Mackey J, Paterson A, Dirix L et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21: 25a (abstr).
42. Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21: 968-975.
43. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413-1424.
44. Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18: 724-733.
45. Ackland SP, Anton A, Breitback GP et al. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. J Clin Oncol 2001; 19: 943-953.
46. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of transtuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
47. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
48. The Australia/New Zealand Breast Cancer Trials Group. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine treatment and cytotoxic therapy given sequentially or in combination. J Clin Oncol 1986; 4: 186-193.
49. Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460.
50. Pavlacis N, Stockler M. Bisphosphonates in breast cancer. Cochrane Database of Systemic Reviews, Issue 1. Oxford: Update Software, 2002.